Logo

ELN

Benchling Raises $14.5M in Series B Round

Benchmark led a new investment round in digital lab notebook maker Benchling, which claims 500 percent year-over-year growth in annual recurring revenue.

Core Informatics Launches Validated Cloud Platform to Provide Alternative for Regulated Labs
Premium

Core Informatics has satisfied Good Manufacturing Practice, Good Laboratory Practice, and Good Clinical Practice guidelines for the cloud version of its product.

ELN Users in Pharma, Academia, Highlight Need to Support Internal and External Collaborations
Premium

By Uduak Grace Thomas

Johns Hopkins Selects Sapio's LIMS for Epigenetic Research
Premium

Sapio Sciences said this week that the Epigenetics Center of the Institute for Basic Biomedical Sciences at Johns Hopkins University has licensed its Exemplar Laboratory Information Management System and Electronic Lab Notebook software.

Accelrys Acquires Contur Software for $13.1M

Accelrys said Contur's offerings will complement the Symyx Notebook that the firm acquired through its merger with Symyx last year.
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.